Aardvark Therapeutics announced the departure of COO Bryan Jones, Ph.D., effective February 9, 2026, to become CEO of its new wholly-owned subsidiary Ardia Therapeutics focused on developing DIA-615 for inflammatory skin diseases. The Board appointed Nelson Sun as COO (in addition to CFO) and Derrick C. Li as Chief Business Officer, effective the same date.
Key takeaways
Bryan Jones, Ph.D. ceased as COO of Aardvark Therapeutics on 2026-02-09 to become CEO of Ardia Therapeutics
Nelson Sun appointed COO effective 2026-02-09 while continuing as CFO; no material compensation change
Derrick C. Li appointed Chief Business Officer effective 2026-02-09
Ardia Therapeutics established as wholly-owned subsidiary to develop DIA-615 topical treatment for psoriasis and other inflammatory skin diseases
Jones' letter agreement accelerates vesting of 17,797 shares and extends option exercise period while employed by Ardia
Jones waived rights under Aardvark Severance Plan and provides transition services for 9 months